Senolytics offer cautious hope for slowing Alzheimer's progression
A new study in Aging suggests senolytics—drugs once linked to anti-aging benefits—may slow Alzheimer’s disease progression. The findings are hopeful for millions affected by the condition, and they come as Thailand’s aging population grows. Experts urge cautious interpretation and careful clinical use as research continues.
Alzheimer’s disease involves amyloid-beta plaques in the brain, a factor associated with cognitive decline. The Thai audience especially understands the burden as families increasingly care for elderly relatives. The international study investigated six compounds known for anti-aging or cognitive-enhancing effects, including dasatinib and nintedanib, both considered senolytics. When tested on brain tissue from individuals with Alzheimer’s, these compounds appeared to selectively reduce pathological forms of brain enzymes linked to the plaques—without harming normal enzyme function.